DISCLAIMERThe information and materials accessed through or made available for use on any of our Sites, including, any information about diseases, conditions, treatments, or medicines, are for informational purposes only. The Content is not intended to be and is not a substitute for professional medical advice, diagnosis, or treatment, and your participation on our Sites does not create a healthcare professional-patient relationship. You should consult a doctor or other qualified health care professional regarding any questions you have about your health or before making any decisions related to your health or wellness. Call your doctor or 911 immediately if you think you may have a medical emergency.
Trusted Resources: News & Events
Latest announcements and gatherings
The U.S. Food and Drug Administration (FDA) has awarded $2 million to support a Phase 2 clinical trial testing whether daily supplementation of vitamin D reduces the risk of respiratory complications in children and adolescents with sickle cell disease (SCD).
Gary M. Brittenham, MD, a pediatrician and professor at Columbia University Irving Medical Center in New York, was the recipient of the four-year grant.
The ViDAS-2 study will compare the effectiveness of a daily dose of oral vitamin D3 (3,333 IU/day) with a monthly dose (100,000 IU/month) over two years. It is intended to determine if daily supplementation can reduce more rapidly the rate of respiratory events — including respiratory infections, asthma exacerbations, or acute chest syndrome events — and lead to improvements in pulmonary and immune function.
news & eventsAlzheimer’s Treatment Memantine Shows Promise in Treating Sickle Cell DiseaseMemantine, a standard treatment for Alzh...
education & researchPH and Sickle Cell DiseaseSickle cell disease (SCD), a type of ane...
education & researchInhaled steroids reduce pain and sVCAM levels in individuals with sickle cell disease: A triple-blind, randomized tr...Clinical and preclinical data demonstrat...
news & eventsProlong Pharma’s Sanguinate Shows Promise in Reverting Shape of Red Blood Cells in SCDProlong Pharmaceuticals’ investigation...
news & eventsInvestigational Oral Inhibitor IMR-687 Shows Promising Results in Ongoing Phase 2 Clinical TrialImara’s investigational oral inhibitor...
news & eventsFirst Sickle Cell Patient Dosed in Phase 2a of IMR-687This morning, Imara Inc. announced that ...
news & eventsShakir Cannon, advocate for minority health, diesShakir Lateef Cannon, a 34-year-old advo...
send a message
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.